Zynerba Pharmaceuticals (ZYNE) Stock Rating Reaffirmed by HC Wainwright

Zynerba Pharmaceuticals (NASDAQ:ZYNE)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Thursday, MarketBeat.com reports. They presently have a $23.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 92.31% from the company’s previous close.

Several other equities research analysts also recently issued reports on ZYNE. Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, November 14th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th. Cantor Fitzgerald set a $17.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 20th. Canaccord Genuity set a $18.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 4th. Finally, Piper Jaffray Companies increased their price objective on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a research report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the stock. Zynerba Pharmaceuticals currently has an average rating of “Hold” and an average target price of $17.50.

Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down $0.13 during trading hours on Thursday, reaching $11.96. 196,933 shares of the company’s stock traded hands, compared to its average volume of 380,763. Zynerba Pharmaceuticals has a 1 year low of $5.42 and a 1 year high of $25.95. The company has a market capitalization of $168.48, a P/E ratio of -4.64 and a beta of 5.82.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.05). During the same quarter in the previous year, the company earned ($0.67) EPS. equities research analysts predict that Zynerba Pharmaceuticals will post -2.48 earnings per share for the current year.

In related news, major shareholder Michael Rapp acquired 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was bought at an average price of $12.99 per share, with a total value of $194,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.91% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP bought a new position in Zynerba Pharmaceuticals in the third quarter valued at $263,000. Virtu KCG Holdings LLC bought a new position in Zynerba Pharmaceuticals in the second quarter valued at $535,000. Teachers Advisors LLC bought a new position in Zynerba Pharmaceuticals in the second quarter valued at $341,000. Perceptive Advisors LLC grew its position in Zynerba Pharmaceuticals by 230.7% in the third quarter. Perceptive Advisors LLC now owns 130,700 shares of the company’s stock valued at $1,320,000 after purchasing an additional 230,700 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Zynerba Pharmaceuticals by 192.1% in the second quarter. Bank of New York Mellon Corp now owns 35,529 shares of the company’s stock valued at $602,000 after purchasing an additional 23,364 shares in the last quarter. 26.42% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/01/hc-wainwright-initiates-coverage-on-zynerba-pharmaceuticals-zyne.html.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply